🤝
Make a deal with GSK
🔒 Paid proposals held safely in escrow — released only when the work's approved.
Followers
233.8K
Posts
14.9K
Following
701
Account age
19 yrs
💰 Suggested sponsorship rate
$1.3K – $2.1K / sponsored post
Estimated from audience size & typical reach — every deal is negotiable and held in SocialDB escrow.
🎁 Free analysisfor GSK
Known for
5.1K views
#News for #investors and #media:
Following today’s agreement to acquire Nuvalent, Inc., our CEO Luke Miels shares why this acquisition is strategically important to our oncology business as we continue to strengthen our pipeline and commitment to patients.
Read more from Luke
4.5K views
Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration
3.3K views
#Investors: Join our webcast (14:00 BST, 09:00 EST) to hear our CEO Luke Miels and other members of our senior leadership team including R&D experts talk about our Q2 2026 results and plans to accelerate growth. $GSK
3.2K views
#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
Find out more in the press release:
📊 Post performance
2.7K
Avg views / post
1.2%
Reach vs followers
Apr 2007
On X since
🔥 Top post: #News for #investors and #media: Following today’s agreement t · 5.1K views
📊 Activity & format
Posting cadence
2 / week
Posts several times a week.
Content mix
Mostly video
Recent: 14 video · 4 image · 0 text.
Follower / following
334×
Follows 701 back. A strong ratio — an audience that follows them, not a follow-for-follow network.
Recent posts
View on X ↗
🔥 Top post
#News for #investors and #media:
Following today’s agreement to acquire Nuvalent, Inc., our CEO Luke Miels shares why this acquisition is strategically important to our oncology business as we continue to strengthen our pipeline and commitment to patients.
Read more from Luk…
▶
#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, @ViiVHC.
Find …
Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus.
This will feature state-of-the-art, tech-enabled labs and infrastructure, providing GSK scientists with access to a world-cl…
#Investors: Join our webcast (14:00 BST, 09:00 EST) to hear our CEO Luke Miels and other members of our senior leadership team including R&D experts talk about our Q2 2026 results and plans to accelerate growth. $GSK
▶
Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosyste…
▶
#News for #investors and #media: Today our licensor Hansoh Pharma announced another positive pivotal dataset on an investigational antibody-drug conjugate in our oncology pipeline.
Learn more: https://t.co/CAQ0Fgsc4O
▶
#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026.
🔗 Find out more in the press release: h…
▶
#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat ROS1-positive non-small cell lung cancer.
Learn more: https://t.co/NqrFxuGgh1
#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
Find out mor…
▶
News for #Media and #Investors: EMA has accepted our submission to update the label of one of our vaccines.
Learn more: https://t.co/Z9Hjl4iE3Z
▶
#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health.
Learn more: https://t.co/K1…
▶
#News for #investors and #media:
Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more…
▶
#News for #Media and #Investors: Today we announced interim positive headline results from our phase II trial evaluating one of our immuno-oncology therapies.
Learn more: https://t.co/x0qoN5eA6V
💡 Facts
🗓️Joined X in 2007 — 19 years ago.
👁️Averages 2.7K views per post.
📤Posts about 2× per week.
💬0.01% engagement rate.
🏅Earned the 100K Followers for passing 100K followers.
🕵️ Fake follower check
Estimated37/100
Low
Credibility score
66%
Mixed
Real audience
Medium
Fake-follower risk
High
Data confidence
- Est. 66% real, active audience · Medium fake-follower risk.
- Low engagement (~1.2% of followers engage each post) — a sign of an inflated or inactive audience.
- Organic base — far more followers than accounts it follows.
- Established account (19+ years old).
- 0.01% engagement — below the ~14.4% typical for this size.
Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.
About
We are uniting science, technology and talent to get ahead of disease together.
Our community guidelines: http://gsk.to/socialmedia
📸 Gallery
🔀 Audience overlap
EstimatedEstimated shared audience with similar creators — useful for avoiding overlap (or doubling down) when planning a campaign.
Rudimental
18%
WoW
17%
Blue Team Con
16%
Indian Coast Guard
14%
Omyurice🔜 FURUM2025
13%
JUNGE FREIHEIT
10%
More like this
Find more →Frequently asked questions
How much does GSK charge for a sponsorship?
GSK hasn't published fixed prices yet. Send a proposal through SocialDB and agree terms directly — your payment is held in escrow until the work is approved.
How do I contact GSK for a brand deal or collaboration?
Send a paid deal or collab request right here on SocialDB — we notify GSK, and once they accept, your payment is held safely in escrow and released when the work is approved. You don't need to track down an email.
How many followers does GSK have?
GSK has 233,798 followers on X.
✉ Message GSK
Reaching out to influencers is a Pro feature. Upgrade to message any influencer directly — perfect for brands and agencies booking sponsorships.
- ✓ Message any influencer from their listing
- ✓ The influencer gets notified by email
- ✓ Manage every conversation in one inbox
Already Pro? Log in.
🎤 Event / appearance with GSK
Booking an event / appearance is a Pro feature. Upgrade to book GSK for an in-person or virtual appearance — payment held safely in escrow until the event is done.
- ✓ Book them for events, livestreams, panels & more
- ✓ GSK gets notified by email
- ✓ Fee held in escrow, released after the appearance
Already Pro? Log in.
🚀
You're out of free requests this month
Free accounts get 5 per month. Go Pro for unlimited sponsor pitches, collab requests & sponsorship deals — plus featured placement, the Verified badge, free withdrawals and more.
Upgrade to Pro — $9.95/mo →Your free limit resets on the 1st of next month.
Auto-generated from X's public data — no affiliation with or endorsement by SocialDB. Is this you? Claim it · Remove